Eli Lilly (LLY) reported $8.77 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 26%. EPS of $2.58 for the same period compares to $1.62 a year ago. The ...
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its ...
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...
Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...